Biogenerics After All? US FDA Wants Biosimilar Process To Mirror Small Molecules
CDER Director Talks Modernization Of Biosimilar Pathway
The US FDA seems poised to move away from the ‘quite burdensome’ testing framework it currently uses for biosimilars (Shutterstock) 
